Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
This study has been completed.
Study NCT01188577 Information provided by Amphastar Pharmaceuticals, Inc.
First Received on August 24, 2010. Last Updated on January 23, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Asthma
Bronchospasm
Wheezing
Shortness of Breath
Additional conditions recognized in this trial
Bronchial Spasm
Dyspnea
Respiratory Sounds
More general conditions related to this trial
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiration Disorders
Respiratory Hypersensitivity
Respiratory Tract Diseases
Signs and Symptoms
Signs and Symptoms, Respiratory
Interventions listed in this trial
Epinephrine Inhalation Aerosol, HFA
Epinephrine Inhalation Aerosol
Additional drug interventions recognized in this trial
Epinephrine
Epinephryl borate
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-Agonists
Adrenergic beta-Agonists
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Mydriatics
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sympathomimetics
Therapeutic Uses
Vasoconstrictor Agents
Sponsors listed in this trial
Amphastar Pharmaceuticals, Inc.
Back to top of Main Content
